BM
EWTX icon

Bridger Management’s Edgewise Therapeutics EWTX Stock Holding History

Bridger Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,700
Closed -$1.64M – 27
2025
Q1 		$1.64M Hold
74,700
– – 0.82% 23
2024
Q4 		$1.99M Hold
74,700
– – 1.07% 20
2024
Q3 		$1.99M Buy
+74,700
New +$1.49M 1% 21

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bridger Management's EWTX Position: Q2 2025 in Review

Bridger Management sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 74,700 shares — an estimated $1.64M sold.

Bridger Management first reported a position in EWTX in Q3 2024 and held it in 3 quarters. The position peaked at $1.99M in Q4 2024. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

  • Bridger Management reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bridger Management sold 74,700 Edgewise Therapeutics shares in Q2 2025, an estimated $1.64M.
  • Bridger Management first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 3 quarters.
  • Bridger Management's Edgewise Therapeutics position peaked at $1.99M in Q4 2024.
  • 178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on Bridger Management's 13F filing for Q2 2025, filed 11 Aug 2025.